Ira Fenton, DO
Rheumatology · Libertyville, ILNPI 1477551752
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,215 of the $36,751 with a category attached, or 71.3%. 60 manufacturers reported payments, led by Amgen at 31.0% of the total. Reporting peaked in 2022 at $9,958 and has fallen 55.7% since, to $4,407 in 2025. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,276 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- AbbVie$5K
- AstraZeneca$3K
- Biogen$2K
- UCB, Inc.$2K
- Novo Nordisk$1K
- plus $12K from 54 others
Across 218 payments — averaging $2951.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$566K
- Novartis$66K
- Eli Lilly$10K
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$8,41023%
- Travel & lodging$1,4724%
- Food & beverage$26,21571%
- Education$6342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,751 in reported general payments places this provider in the 90th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TavneosAvacopan | 11 | $183,226 |
| Enbrel SureclickEtanercept | 18 | $165,629 |
| EnbrelEtanercept | 13 | $113,805 |
| Xeljanz XrTofacitinib Citrate | 15 | $86,456 |
| OzempicSemaglutide | 64 | $73,218 |
| OxycontinOxycodone Hcl | 13 | $28,372 |
| EliquisApixaban | 29 | $28,250 |
| FarxigaDapagliflozin Propanediol | 34 | $27,656 |
| Xtampza ErOxycodone Myristate | 20 | $26,347 |
| JardianceEmpagliflozin | 28 | $25,943 |
| LinzessLinaclotide | 20 | $25,456 |
| RybelsusSemaglutide | 15 | $24,507 |
| TradjentaLinagliptin | 24 | $24,023 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $21,330 |
| XareltoRivaroxaban | 15 | $19,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTavneos, Enbrel, Prolia | $11,380 | $316,27835 claims |
| Novo NordiskOzempic, Rybelsus | $1,443 | $97,72479 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr | $851 | $77,58996 claims |
| PfizerEliquis, Abrysvo | $1,432 | $36,26554 claims |
| Lilly USA, LLCMounjaro, Trulicity | $927 | $35,26032 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,269 | $32,22555 claims |
| AstraZenecaFarxiga | $2,952 | $27,65634 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $209 | $26,34720 claims |
| AbbVieLinzess | $4,908 | $25,45620 claims |
| Johnson & JohnsonXarelto | $1,030 | $19,82115 claims |
| MerckJanuvia | $143 | $17,79628 claims |
| Hikma Pharmaceuticals USABuprenorphine | $131 | $12,73548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Libertyville
- Manish JainChicago$1.9M
- Lori SiegelBannockburn$1.5M
- Alfonso BelloGlenview$611K
- Theodore PincusChicago$524K
- Angela CrowleyWillowbrook$483K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Jeffrey HorvathSpringfield$246K
- Robert HozmanSkokie$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.